Onconetix (ONCO) Long-Term Deferred Tax (2021 - 2026)

Onconetix (ONCO) posted quarterly Long-Term Deferred Tax of $225000.0 for Q1 2026, little changed quarter-over-quarter from $225000.0 in Q4 2025.

Onconetix (ONCO) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends

Onconetix (ONCO) has reported Long-Term Deferred Tax for 6 consecutive years, with $225000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $225000.0; the TTM figure through Mar 2026 stood at $225000.0 (changed N/A YoY), while the FY2025 annual figure was $225000.0, down 25.0% from the prior year.
Long-Term Deferred Tax held at $225000.0 in Q1 2026 per ONCO's latest filing, from $225000.0 in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $3.0 million in Q4 2022 and bottomed at $150000.0 in Q3 2025.
Historically, Long-Term Deferred Tax has averaged $553037.8 across 5 years, with a median of $366113.0 in 2023.
Annual changes were most pronounced in 2022 — Long-Term Deferred Tax jumped 120625.06% — and 2023, when it plunged 87.74%.
Onconetix's Long-Term Deferred Tax stood at $3.0 million in 2022, then slumped by 87.74% to $366113.0 in 2023, then dropped by 18.06% to $300000.0 in 2024, then retreated by 25.0% to $225000.0 in 2025, then changed by 0.0% to $225000.0 in 2026.
Business Quant data shows ONCO's Long-Term Deferred Tax at $225000.0 in Q1 2026, $225000.0 in Q4 2025, and $150000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00

Download Data